Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lorlatinib - Pfizer

Drug Profile

Lorlatinib - Pfizer

Alternative Names: [14C]Lorlatinib; LORBRENA; LORVIQUA; Lorviqua; PF-06463922; PF-6463922

Latest Information Update: 06 Dec 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Developer New Approaches to Neuroblastoma Therapy Consortium; Pfizer; The EVAN Foundation; University of Southern California
  • Class Antineoplastics; Aza compounds; Benzoxazines; Nitriles; Pyrazoles; Pyridines; Small molecules
  • Mechanism of Action Anaplastic lymphoma kinase inhibitors; ROS1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Non-small cell lung cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Non-small cell lung cancer
  • Phase II Lymphoma
  • Phase I Cancer; Neuroblastoma

Most Recent Events

  • 19 Nov 2019 Registered for Non-small cell lung cancer (Late-stage disease, Second-line therapy or greater) in Australia (PO) - provisional approval
  • 16 Sep 2019 Intergroupe Francophone de Cancerologie Thoracique initiates enrolment in the phase II ORAKLE trial for Non small cell lung cancer (Metastatic disease, Late-stage disease, Monotherapy, Second-line therapy or greater) in France (EudraCT 2019-002230-37) (NCT04111705)
  • 22 Aug 2019 Pfizer initiates enrolment in a phase I trial in healthy volunteers in Belgium (NCT03961997) (EudraCT2019-001455-40)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top